Last reviewed · How we verify
Background ART Regimen
At a glance
| Generic name | Background ART Regimen |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Contribution of Dolutegravir to Obesity and Cardiovascular Disease (PHASE4)
- Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment (PHASE3)
- Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140 (PHASE2, PHASE3)
- Prospective Observational Epidemiologic Study of Maraviroc's Safety
- Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND) (PHASE4)
- A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (PHASE3)
- Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents (PHASE1, PHASE2)
- Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Background ART Regimen CI brief — competitive landscape report
- Background ART Regimen updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI